Sydney, Australia, 30 August 2019: Recce Pharmaceuticals Ltd (ASX:RCE) (Recce or the Company), the Company developing a New Class of Broad Spectrum Antibiotics, today announced a successful grant application as one of five Industrial Partners in collaboration with 16 University and Public Health Organisations, to establish a National Anti-Microbial Resistant (AMR) Research Hub (the Hub) in Sydney, Australia to combat antimicrobial resistance.
The Australian Research Council (ARC) has awarded almost AU$5 million to the Hub. Recce and other leading industry partner organisations will engage with Australia’s key researchers and wider stakeholders to address the urgent challenge of antimicrobial resistance.
Recce Chairman Dr John Prendergast said, “If the world is to address the increasing threat of antimicrobial resistance, it’s vital that Governments, industry and academic researchers work together. The funding for this valuable interdisciplinary collaboration will help maximise the value of our product pipeline and accelerate our efforts to identify and commercialise new antibiotics for patients and clinicians worldwide.”
“Participation aligns with our goals of working to make a contribution to global health and we look forward to working with the Hub committee as a key industry partner,” he said.
The Hub is a collaboration between the following organisations:
Public Research Organisations:
Other collaborating organisations: Murdoch Children's Research Institute, WHO Collaborating Centre for Sexually Transmitted Infections and Antimicrobial Resistance, Melbourne Sexual Health Clinic, Western Sydney Sexual Health Centre, Sydney Sexual Health Centre, PNG Institute of Medical Research, and Thai Red Cross AIDS Research Centre.
About Recce Pharmaceuticals Ltd
Recce Pharmaceuticals Ltd (ASX: RCE) is pioneering the development and commercialisation of a New Class of Synthetic Antibiotics with Broad Spectrum activity designed to address the urgent global health problem of antibiotic resistant superbugs. Recce antibiotics are unique – their potency does not diminish even with repeated use, which is a common failure associated with existing antibiotic use and the resulting emergence of resistant superbugs. Patented lead candidate RECCE® 327, wholly owned and manufactured in Australia, has been developed for the treatment of blood infections and sepsis derived from E. coli and S. aureus bacteria – including their superbug forms. The FDA has awarded RECCE® 327 Qualified Infectious Disease Product designation under the Generating Antibiotic Initiatives Now (GAIN) Act – labelling it for Fast Track Designation, plus 10 years of market exclusivity post approval. Recce wholly owns its automated manufacturing, ready to support first-in-human clinical trials. Recce’s anti-infective pipeline seeks to exploit the unique capabilities of RECCE® technologies targeting synergistic, unmet medical needs.
For further information please visit www.recce.com.au
Issued for and on behalf of Reece Phamaceuticals Ltd by Instinctif Partners.
For more information please contact Recce@instinctif.com
Sue CharlesManaging Partner